Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance (PEGLIST C)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by French National Agency for Research on AIDS and Viral Hepatitis.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
French National Agency for Research on AIDS and Viral Hepatitis Identifier:
First received: June 22, 2009
Last updated: February 20, 2012
Last verified: February 2012
The purpose of this study is to test whether the correction of insulin resistance with pioglitazone, will improve the response to antiviral treatment.

Condition Intervention Phase
Chronic Hepatitis C
Insulin Resistance
Drug: Pioglitazone
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: ANRS HC 22, PEGLIST-C, Multicenter, Randomized Controlled Trial of Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C, Non 2 or 3 Genotypes and Insulin Resistance

Resource links provided by NLM:

Further study details as provided by French National Agency for Research on AIDS and Viral Hepatitis:

Primary Outcome Measures:
  • Decrease in the HOMA score below 2 after 4 months of treatment with pioglitazone or placebo(at W16). The efficiency is defined as a higher proportion of subjects with HOMA <2 in the pioglitazone group than in the group treated with placebo pioglitazone. [ Time Frame: W16 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Kinetics of decrease in viral response to pegylated interferon. Early virological response rates. Rates of sustained virological response. Effect on steatosis [ Time Frame: EVR at W16 and W28 SVR at W88 ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: December 2009
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Pioglitazone, 16 weeks before and during antiviral combination therapy
Drug: Pioglitazone
Pioglitazone, 45 mg QD (30 mg QD the first month)
Placebo Comparator: 2
Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
Drug: Placebo
Placebo 45 mg QD (30 mg QD the first month)

Detailed Description:
In patients infected with genotypes 1, 4, 5 and 6, the response rate to antiviral therapy remains suboptimal (less than one in two patients have a sustained virological response), which justifies the search for strategies optimizing the results of antiviral therapy. Some factors associated with non response have been identified. Among the modifiable factors, numerous series have shown that insulin resistance adversely impacts the rate of sustained virological response. The aim of this study is to determine whether the pharmacological correction of insulin resistance through therapy with glitazones restores higher rates of viral eradication and to determine the impact on the kinetics of viral response. Patients will be randomized to receive pioglitazone or placebo starting 4 months before initiating pegylated interferon and ribavirin and continued throughout the whole antiviral treatment period.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years old or older
  • Chronic HCV infection documented by PCR with genotype HCV-1, 4, 5 or 6
  • Naive Patient(never treated with antivirals for HCV)
  • HOMA score higher than 2.5
  • Patient for which the investigator decided to start antiviral treatment for chronic hepatitis C

Exclusion Criteria:

  • Cardiovascular disease: heart failure stage NYHA II, III or IV, unstable angina, myocardial infarction in the previous year, cardiac surgery or stroke
  • Alcohol consumption exceeding 40 g / day
  • Decompensated liver disease: Child-Pugh B 8 or higher, or one of the following : bilirubin over 35 mol / L, TP below 50%, ascites, encephalopathy
  • Hepatocellular carcinoma or any other neoplasm (except if in remission for > 5 years)
  • Other documented chronic liver disease
  • Insulin treated diabetes
  • HBV or HIV co-infection infection confirmed
  • Thrombocytopenia below 50 000/mm ³; neutropenia below 750/mm ³ or hemoglobin below 11 g / dL
  • Drug-induced steatosis(tamoxifen, glucocorticosteroids, amiodarone, tetracyclines).
  • Bone marrow or solid organ transplantation
  • Pregnancy or breastfeeding, or desire for pregnancy during the study period.
  • Patients under legal protection or unable to express their consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00927290

Hôpital Pitié Salpêtrière, Service d'hépatogastroentérologie
Paris, France, 75013
Sponsors and Collaborators
French National Agency for Research on AIDS and Viral Hepatitis
Principal Investigator: Vlad RATZIU, MD, PHD Hôpital Pitié--Salpêtrière, 83 Bd de l'Hôpital 75651 Paris cedex 13, FRANCE
  More Information

Responsible Party: French National Agency for Research on AIDS and Viral Hepatitis Identifier: NCT00927290     History of Changes
Other Study ID Numbers: 2008-006225-14 
Study First Received: June 22, 2009
Last Updated: February 20, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
hepatitis C; insulin resistance; glitazones; pioglitazone; steatosis; viral kinetics; antiviral response

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Insulin Resistance
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Glucose Metabolism Disorders
Metabolic Diseases
Antiviral Agents
Hypoglycemic Agents
Physiological Effects of Drugs
Antineoplastic Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action processed this record on December 08, 2016